Short-Term Effects of Cannabis Therapy on Spasticity in MS

INVESTIGATOR: Jody Corey-Bloom, M.D., Ph.D.

STUDY LOCATION: University of California, San Diego

PROJECT TITLE: Short-Term Effects of Cannabis Therapy on Spasticity in MS

PROJECT TYPE: Clinical Study

STATUS: COMPLETE

RESULTS:

Thirty-seven participants were randomized at the start of the study, 30 of whom completed the trial. Treatment with smoked cannabis resulted in a significant reduction in spasticity using an objective clinician-rated measure. The placebo-controlled trial also resulted in reduced perception of pain, although participants also reported short-term, adverse cognitive effects and increased fatigue. No serious adverse events occurred during the trial.

The full results of this study have been published in CMAJ.

ABSTRACT:

Multiple Sclerosis (MS) is the most common debilitating neurologic disease of young people, affecting at least 250,000 persons in the US, often between the ages of 20 and 40. Symptom manifestation varies considerably from person to person; however, one frequently noted concomitant is spasticity, which causes pain, spasms, loss of function and difficulties in nursing care. The present application is designed to explore the short-term effectiveness and safety of medicinal cannabis on spasticity in patients with MS. There has been significant public discussion on the potential therapeutic uses of cannabis for various neurologic conditions, including MS; however, evidence that cannabis relieves spasticity produced by MS is largely anecdotal. Large-scale trials or controlled studies to compare cannabis or THC with currently available therapies for spasticity have not been performed. There is no published evidence that cannabinoids are superior or equivalent to available anti-spasticity therapies and potential side effects of cannabis need to be clarified. This proposed two-year project aims to examine spasticity and global functioning in 30 MS patients before and after treatment with smoked cannabis in a placebo-controlled, randomized, cross-over design. It is expected that MS subjects will demonstrate improvement in spasticity but impairment on cognitive measures of attention, concentration, and memory assessed before and after medicinal cannabis treatment. Patients will be measured at baseline and for three days after each treatment initiation using sensitive measures of spasticity, cognition, neuropsychiatric features, treatment-emergent effects, and global measures of functioning. Thus, the application's primary goal is to obtain objective assays of short-term efficacy and safety in MS patients treated for spasticity with medicinal cannabis.

PUBLICATIONS:

Type:

Title:

Journal Article Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte T, Bentley H, Gouaux B. (2012). Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ. 2012 Jul 10;184(10):1143-50. doi: 10.1503/cmaj.110837. Epub 2012 May 14.
Meeting Abstract Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte T, Bentley H, Gouaux B. Short-Term Effects of Medicinal Cannabis on Spasticity in Multiple Sclerosis. Poster presented at the 60th Annual Meeting of the American Academy of Neurology (Chicago, IL). 2008.

Smoking weed: When is someone too high to drive?

NBC News, January 3, 2019

It used to be the stuff of stoner comedies and “Just Say No” campaigns. Today, marijuana is becoming mainstream as voters across the country approve ballot questions for legalization or medical use.

In response, state governments are testing ways to ensure that the integration of this once-illicit substance into everyday life doesn’t create new public health risks. These efforts are sparking a difficult question: At what point is someone too high to get behind the wheel?

The answer is complicated. Brain scientists and pharmacologists don’t know how to measure if and to what extent marijuana causes impairment.

Read the rest of the story here


What’s behind the rise in cannabis-infused products?

Alex Hannaford, BBC, November 22, 2018

There’s vape oil, pain-relief cream, patches, sweets (gummy bears, sour snakes, rainbow bites – take your pick), capsules and compounds.

Cannabidiol, or CBD as it’s better known – a naturally occurring extract of the cannabis sativa plant – is now so ubiquitous in the US, you’d be forgiven for thinking there are few places it's not available and few ailments it cannot treat.

Users say they take it for everything from muscle aches and anxiety to arthritis, epilepsy and Post Traumatic Stress Disorder.

And let’s not forget Fido. There’s CBD oil for him too – with added bacon flavour.

Read the article here


Cannabis 101: A Q&A with UC San Diego Health’s cannabis experts

Gabrielle Johnston, MPH, UC San Diego Health, October 30, 2018

It seems like everywhere you turn cannabis or cannabis derivatives can be found. From ingredients in coffee and smoothies to being marketed as medicine, a cannabis craze seems to be sweeping the country. Since 2000, UC San Diego School of Medicine’s Center for Medicinal Cannabis Research and its affiliated researchers have been studying marijuana and its derivatives, their effects on mind and body and their therapeutic potential.

We asked experts to cut through the hyperbole and haze to answer some burning questions.

Read the Q&A here


San Diego company testing marijuana-derived multiple sclerosis therapy

Gary Robbins, San Diego Union Tribune, October 10, 2018

Emerald Health Pharmaceuticals of San Diego has begun using a marijuana-derived therapy to experimentally treat small numbers of people who suffer from multiple sclerosis and scleroderma, a pair of autoimmune diseases.

The small, phase 1 safety trial involves CBD, a compound found in marijuana. CBD has caught the attention of researchers because it does not get people high, and it has anti-inflammatory properties.

The trial is meant to determine whether the therapy is safe, what dose should be used, and if there are any side effects or related problems.

Emerald Health says it also is developing another non-psychoactive compound found in marijuana — CBG — for possible use in treating patients with Huntington’s disease and Parkinson’s disease.

UC San Diego is preparing to use CBD in a clinical trial that’s meant to people who suffer from epilepsy.

Read the story here


More News

Click here to access the CMCR news archives.

Igor Grant, MD

Introduction/Overview
CMCR Symposium, June 2018


Daniele Piomelli, MD, PhD, PharmD

The health impact of cannabis
CMCR Symposium, June 2018


Ziva Cooper, PhD

Therapeutic potential of cannabis for pain alone and as an adjunct to opioids
CMCR Symposium, June 2018


Iain McGregor, PhD

Medicinal cannabis research down under: Introducing the Lambert Initiative for Cannabinoid Therapeutics
CMCR Symposium, June 2018


Thomas Marcotte, PhD

Cannabis and public safety: The challenge of cannabis-impaired driving
CMCR Symposium, June 2018


Alan Budney, PhD

Medicinal cannabis / legalization and the development of cannabis use problems
CMCR Symposium, June 2018


Ryan Vandrey, PhD

What's in real-world cannabis?
CMCR Symposium, June 2018


Copyright © 2019 CENTER FOR MEDICINAL CANNABIS RESEARCH. | University of California, San Diego
cmcr@ucsd.edu | HNRP |